HomeCompareCSBI vs JNJ

CSBI vs JNJ: Dividend Comparison 2026

CSBI yields 1265.42% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSBI wins by $151028087.02M in total portfolio value
10 years
CSBI
CSBI
● Live price
1265.42%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$151028087.05M
Annual income
$130,708,854,941,179.16
Full CSBI calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — CSBI vs JNJ

📍 CSBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSBIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSBI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSBI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSBI
Annual income on $10K today (after 15% tax)
$107,560.90/yr
After 10yr DRIP, annual income (after tax)
$111,102,526,700,002.28/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, CSBI beats the other by $111,102,526,695,964.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSBI + JNJ for your $10,000?

CSBI: 50%JNJ: 50%
100% JNJ50/50100% CSBI
Portfolio after 10yr
$75514043.54M
Annual income
$65,354,427,472,964.52/yr
Blended yield
86.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CSBI
No analyst data
Altman Z
-3.6
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSBI buys
0
JNJ buys
0
No recent congressional trades found for CSBI or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSBIJNJ
Forward yield1265.42%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$151028087.05M$30.5K
Annual income after 10y$130,708,854,941,179.16$4,749.88
Total dividends collected$149521533.30M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSBI vs JNJ ($10,000, DRIP)

YearCSBI PortfolioCSBI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$137,242$126,542.23$10,594$274.49+$126.6KCSBI
2$1,769,928$1,623,078.39$11,294$360.69+$1.76MCSBI
3$21,456,281$19,562,458.62$12,133$476.91+$21.44MCSBI
4$244,593,358$221,635,137.39$13,156$635.42+$244.58MCSBI
5$2,622,981,605$2,361,266,711.36$14,432$854.61+$2622.97MCSBI
6$26,471,881,467$23,665,291,150.18$16,056$1,162.76+$26471.87MCSBI
7$251,536,964,615$223,212,051,444.73$18,175$1,604.53+$251536.95MCSBI
8$2,251,360,050,880$1,982,215,498,742.85$21,009$2,252.68+$2251360.03MCSBI
9$18,989,936,554,871$16,580,981,300,429.26$24,911$3,229.73+$18989936.53MCSBI
10$151,028,087,054,891$130,708,854,941,179.16$30,458$4,749.88+$151028087.02MCSBI

CSBI vs JNJ: Complete Analysis 2026

CSBIStock

Carroll Shelby International, Inc., through its subsidiaries, manufactures and markets performance vehicles and related accessories. It offers authentic continuation cobras, including the Cobra 427 S/C, the Cobra 289 FIA, and the Cobra 289 S/C. The company also sells aftermarket styling and performance parts under the Shelby Performance Parts brand name. In addition, it licenses Shelby brand to third parties in connection with various products, such as vehicles, memorabilia, video games, models, toys, branded apparel, styling, and performance parts. The company sells its vehicles through a proprietary dealer network in North America and Europe. Carroll Shelby International, Inc. is based in Gardena, California.

Full CSBI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CSBI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSBI vs SCHDCSBI vs JEPICSBI vs OCSBI vs KOCSBI vs MAINCSBI vs ABBVCSBI vs MRKCSBI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.